NCT06787612 2026-04-08Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRegeneron PharmaceuticalsPhase 2 Recruiting220 enrolled
NCT06469281 2026-02-03A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRegeneron PharmaceuticalsPhase 1 Recruiting90 enrolled